American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of High-Dose-Rate Brachytherapy

Erickson, Beth; Demanes, D. Jeffrey; Hayes, John K.; Hsu, I‐Chow; Morris, David E.; Rabinovitch, Rachel; Tward, Jonathan D.; Rosenthal, Seth A.

doi:10.1016/j.ijrobp.2010.08.046

Cited by 45 publications

(24 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…HDR and PDR stepping source technology offer the advantage of optimizing dose distribution by varying dwell times [1]. The application of HDR brachytherapy has expanded to many sites, having been used in treatment of gynecological cancer, breast cancer, and prostate cancer [2, 3]. Guedea et al .…”

Section: Introductionmentioning

confidence: 99%

High dose rate brachytherapy for oral cancer

Yamazaki

Yoshida

Yoshioka

et al. 2012

Journal of Radiation Research

View full text Add to dashboard Cite

Brachytherapy results in better dose distribution compared with other treatments because of steep dose reduction in the surrounding normal tissues. Excellent local control rates and acceptable side effects have been demonstrated with brachytherapy as a sole treatment modality, a postoperative method, and a method of reirradiation. Low-dose-rate (LDR) brachytherapy has been employed worldwide for its superior outcome. With the advent of technology, high-dose-rate (HDR) brachytherapy has enabled health care providers to avoid radiation exposure. This therapy has been used for treating many types of cancer such as gynecological cancer, breast cancer, and prostate cancer. However, LDR and pulsed-dose-rate interstitial brachytherapies have been mainstays for head and neck cancer. HDR brachytherapy has not become widely used in the radiotherapy community for treating head and neck cancer because of lack of experience and biological concerns. On the other hand, because HDR brachytherapy is less time-consuming, treatment can occasionally be administered on an outpatient basis. For the convenience and safety of patients and medical staff, HDR brachytherapy should be explored. To enhance the role of this therapy in treatment of head and neck lesions, we have reviewed its outcomes with oral cancer, including Phase I/II to Phase III studies, evaluating this technique in terms of safety and efficacy. In particular, our studies have shown that superficial tumors can be treated using a non-invasive mold technique on an outpatient basis without adverse reactions. The next generation of image-guided brachytherapy using HDR has been discussed. In conclusion, although concrete evidence is yet to be produced with a sophisticated study in a reproducible manner, HDR brachytherapy remains an important option for treatment of oral cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

High dose rate brachytherapy for oral cancer

Yamazaki

Yoshida

Yoshioka

et al. 2012

Journal of Radiation Research

View full text Add to dashboard Cite

show abstract

“…The primary function-specific responsibilities of the brachytherapy team members comprise, but are not limited to [11,[52][53][54][55] …”

Section: Specific Responsibilities Of the Team Membersmentioning

confidence: 99%

NCS Report 30: Code of Practice for Quality Assurance of Brachytherapy with Ir-192 Afterloaders

Steenhuizen¹,

Harbers²,

Hoffmann³

et al. 2018

View full text Add to dashboard Cite

“…With the advent of high-dose-rate brachytherapy (HDR-BRT), having an advantage of avoiding radiation exposure to health care providers and with fractionated radiation scheme, HDR-BRT has replaced low-dose-rate (LDR) and even pulse-dose-rate (PDR) (practiced at few centers) in most centers where BRT is commonly used, as sole or adjunct therapeutic measure, and the use of BRT has been proven in various other sites [5, 6]. The advantage of BRT is that it provides a localized high dose of radiation, with rapid fall-off beyond planning treatment volume or implant treatment volume (PTV/ITV), sparing normal surrounding tissue, and short overall treatment time [7].…”

Section: Purposementioning

confidence: 99%

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Bhalavat¹,

Chandra²,

Pareek³

et al. 2017

jcb

View full text Add to dashboard Cite

Purpose: To evaluate the treatment outcomes with high-dose-rate (HDR) interstitial brachytherapy (HDR-BRT) in head and neck cancers (HNC).Material and methods: Fifty-eight patients with HNC as per American Joint Committee on Cancer (AJCC) TNM staging criteria were analyzed retrospectively between 2008 and 2015. Forty-two patients received external beam radiotherapy (EBRT) with HDR-BRT and 16 patients received BRT alone. The survival was calculated with respect to median biological equivalent doses (BED) and median 2 Gy equivalent dose (EQD 2 ), keeping α/β = 10 for tumor. Loco-regional control and disease free survival was assessed.Results: The median follow-up period was 25 months (2-84 months). The disease-free survival (DFS) probability at year 1 was 82.7%, and 68% at year 7. The overall survival probability was 91.3% at year 1 and 85.8% at year 7. The local control rate was 70%. The rate of recurrence was 30%. Distant metastasis rate was 17.2%. The median BED and EQD 2 , respectively, were 86.78 Gy and 71.6 Gy. The DFS was 74.1% and 75.9% in patients receiving a dose more than median BED and EQD 2 , respectively, and was 64.8% and 61.5% for less than the median dose.Conclusions: The overall outcome was good with implementation of HDR-BRT used alone or as boost, and shows DFS as better when the dose received is more than the median BED and median EQD 2 . The role of HDR-BRT in HNC is a proven, effective, and safe treatment method with excellent long term outcome as seen in this study, which reflects the need for reviving the forgotten art and science of interstitial brachytherapy in HNC.

show abstract

American Society for Radiation Oncology (ASTRO) and American College of Radiology (ACR) Practice Guideline for the Performance of High-Dose-Rate Brachytherapy

Cited by 45 publications

References 104 publications

High dose rate brachytherapy for oral cancer

High dose rate brachytherapy for oral cancer

NCS Report 30: Code of Practice for Quality Assurance of Brachytherapy with Ir-192 Afterloaders

High-dose-rate interstitial brachytherapy in head and neck cancer: do we need a look back into a forgotten art – a single institute experience

Contact Info

Product

Resources

About